drugset / Trial / NCT07401121
Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis
Phase 1
Recruiting
15 enrolled
Celosia Therapeutics Pty Ltd
Novotech (Australia) Pty Limited · collab
NaSequentialOpen-labelTreatment
Summary
This clinical study is in participants with Amyotrophic Lateral Sclerosis and is designed to evaluate the safety and tolerability of the gene therapy CTx1000.
Timeline
- Start
- 2026-01-12
- Primary completion
- 2027-12
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CTx1000 | Unknown | — | Other |